ENDOMETRIAL CANCER

This trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…

This phase 2 trial is testing whether the immunotherapy drug sintilimab can eliminate early-stage (I-II) MSI-H/dMMR endometrial cancer without the need for surgery. About 48 participants will receive sintilimab alone every three weeks. The goal is to see if the drug can produce a…

This trial is testing whether adding elemene liposomes—a compound derived from a traditional Chinese medicinal plant—to standard chemotherapy (carboplatin and paclitaxel) can help people with advanced or recurrent endometrial cancer. Participants will receive either the combinati…

This phase 2 trial is testing whether adding an experimental drug called OK-1 to the standard chemotherapy paclitaxel can shrink tumors in people with advanced or recurrent endometrial cancer. Participants take OK-1 capsules twice daily along with weekly intravenous paclitaxel. T…

This Phase 3 trial tests a new biologic drug (PF-08634404) plus chemotherapy against the approved drug Keytruda plus chemotherapy in 600 women with advanced or recurrent pMMR endometrial cancer. The goal is to see if the new combination helps patients live longer without their ca…

This trial tests whether adding orlistat, a weight-loss drug that blocks fat absorption, to standard progestin therapy can improve treatment response in young women (45 or younger) with early-stage endometrial cancer or atypical endometrial hyperplasia who have low progesterone r…

This phase 3 trial tests whether adding an experimental drug (GSK5733584) to standard immunotherapy can help keep advanced or recurrent endometrial cancer from growing. About 610 adults who have already completed initial chemotherapy with immunotherapy will receive either the new…

This early-phase trial tests a one-time treatment called OPB-201, where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called PRAME. The study will enroll 30 adults with recurrent endometrial cancer or platinum-…

This study tests whether a 28- to 54-week program of weight-loss medication (semaglutide), a hormone-releasing IUD, diet, and exercise is safe and feasible before surgery in women with early endometrial cancer and a BMI of 40 or higher. Eighty participants will be randomly assign…

This study tests whether tirzepatide, a drug used for diabetes and weight loss, can slow or stop the growth of early-stage endometrial cancer or its precursor (EIN) in women with obesity. Forty participants will receive either tirzepatide or no additional treatment for 4 weeks be…

This early-stage study tests a new drug called HH160 in about 56 adults with advanced solid tumors (cancers that have spread). The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. Participants will receive HH160 alone or with other cancer tr…

This study tests whether adding a weight-loss shot (tirzepatide) to standard hormone therapy can better treat early-stage uterine cancer or pre-cancer in overweight women. About 30 participants will either get the standard progesterone IUD alone or the IUD plus tirzepatide. The g…

This phase 2 trial is testing a daily pill called Inavolisib in about 48 people with advanced endometrial cancer that has a specific genetic change (PIK3CA mutation). The drug targets that mutation to try to shrink tumors or stop them from growing. Researchers will measure how ma…

This study tests whether daily adaptive radiotherapy (ART) can safely deliver shorter, more intense radiation treatments for prostate, endometrial, cervical, and rectal cancers. About 264 participants will be randomly assigned to standard radiation or ART, which uses daily imagin…

This study tests a new way to deliver radiotherapy for endometrial cancer after surgery. Using real-time MRI guidance, doctors can target radiation more accurately and reduce damage to nearby organs like the bowel and bladder. About 61 women will receive five high-dose sessions o…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study compares two surgical approaches for women with early-stage, high-risk endometrial cancer that has a p53 gene mutation. One group will get the standard extensive lymph node removal, while the other gets a less invasive sentinel node biopsy. The goal is to see if the si…

This study tests a daily pill called hetrombopag to see if it can safely raise low platelet counts in women with gynecological cancers (like ovarian or cervical cancer) after chemotherapy. About 244 women whose platelets dropped too low will take the drug to help them complete th…

This study tests two immunotherapy drugs (iparomlimab and tuvonralimab) in 30 women with a specific type of endometrial cancer that is mismatch repair-deficient. The goal is to see if the treatment can make the cancer disappear or shrink enough to avoid surgery. Participants must…

This study tests whether using an AI tool to analyze a patient's body composition from a CT scan can help doctors personalize chemotherapy dosing. The goal is to reduce severe side effects like low white blood cell counts in women with endometrial or ovarian cancer. About 294 par…

This phase 2 study tests whether adding the targeted drug fruquintinib to standard chemotherapy (paclitaxel and carboplatin) works better than chemotherapy alone for advanced pMMR endometrial cancer. About 128 participants will be randomly assigned to receive either the combinati…

This study tests a new imaging technique that could help surgeons see if cancer has spread to lymph nodes during surgery for gynecologic cancers like ovarian, endometrial, cervical, and vulvar cancer. The method uses a special microscope to examine lymph node tissue right after i…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study is testing a new medical device that gently collects cells from the vagina to look for signs of ovarian and endometrial cancers. The goal is to see if this less invasive method can accurately detect these cancers compared to standard tests. About 300 women, some with c…

This observational study will test a new molecular test called CISENDO, which looks at DNA methylation in cells from a routine cervical smear. The goal is to see if it can accurately detect endometrial cancer or precancerous lesions in women at medium-to-high risk. Researchers wi…

This trial tests whether mind-body practices like breathwork, meditation, and gentle yoga can improve quality of life, stress, and sleep in people who have recently finished cancer treatment. Participants will practice these techniques weekly for six weeks while wearing an activi…

This study tests if a newer, shorter course of radiation therapy (MH-ART) is as good as the standard longer course (CF-IMRT) for women who have had surgery for cervical or endometrial cancer. The goal is to see if the new approach causes fewer side effects and improves quality of…

This study looks at whether hand and foot exercises can reduce nerve pain (numbness, tingling) and improve quality of life in adults aged 65+ with gynecological cancer who are on chemotherapy. About 74 participants will do these exercises to see if they help with chemotherapy sid…

This study aims to develop an online educational tool for women diagnosed with endometrial cancer. Participants will use a website to access educational content, complete surveys, and provide feedback on its usability. The goal is to create a resource that can be made widely avai…

This study will include about 2,748 people with breast, gynecologic, or pancreatic cancer. Researchers want to see if adding patient-reported outcomes—like symptoms, preferences, and travel distance—to tumor board discussions helps doctors make better treatment decisions. The goa…

This study looks at whether a blood test that detects tumor DNA can help decide if women with early-stage endometrial cancer need radiation after surgery. About 1,010 women will be followed for two years. Those with a negative blood test may safely skip radiation, while others re…

This study compares two minimally invasive surgical methods for early-stage endometrial cancer: standard laparoscopy (small abdominal cuts) and vNOTES (surgery through the vagina with no visible scars). Researchers will enroll 160 women to see how well each method finds sentinel …

This study will ask 50 people aged 35 and older with abnormal uterine bleeding to collect daily urine samples and track their bleeding at home for several months. Researchers will use a home monitor to measure hormone levels and see if certain patterns are linked to uterine cance…

This study is testing a new blood test that looks for tiny bits of cancer DNA (called minimal residual disease or MRD) in patients with endometrial or cervical cancer. The goal is to see if this test can find cancer coming back earlier than standard scans or exams. About 600 part…

This study will test 20 people with endometrial cancer who also have a BRCA mutation in their tumor. Researchers will look for inherited (germline) gene changes using a blood test. The goal is to better understand genetic risks in this type of cancer. No treatment is given; it is…

This study looks at 100 women aged 18-45 with early-stage endometrial cancer who want to preserve their fertility. Researchers will analyze the tumor's molecular subtype (based on gene testing) to see how it affects response to hormone therapy and recurrence rates. The goal is to…

This study looks back at the medical records of 200 people treated for gynecological cancers (like ovarian, cervical, or uterine cancer) at Assiut University Hospital between 2022 and 2025. The goal is to measure how long patients survive after diagnosis and compare those numbers…

This study will examine tissue samples from 50 people with type 1 endometrial cancer to measure levels of a protein called METTL-14. Researchers want to see if higher or lower amounts of this protein are linked to how aggressive the cancer is and how long patients live without th…